Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database
From MaRDI portal
Publication:5977801
DOI10.1111/j.1365-2125.2011.04037.xWikidataQ35629751 ScholiaQ35629751MaRDI QIDQ5977801
Jean‐Louis Montastruc, Maryse Lapeyre‐Mestre, Agnès Sommet, Haleh Bagheri
Publication date: 9 November 2011
Published in: British Journal of Clinical Pharmacology (Search for Journal in Brave)
Related Items (1)
This page was built for publication: Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database
